| Title: |
COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies:A Nationwide Cohort Study |
| Authors: |
Hofsink, Quincy; Lissenberg-Witte, Birgit I.; Haggenburg, Sabine; Goorhuis, Abraham; Hazenberg, Mette D.; Rutten, Caroline E.; Den Tex, Paul; De Vries, Elisabeth G.E.; Van der Veldt, Astrid A.M.; Kemmeren, Jeanet M.; De Keizer, Nicolette F.; Huijgens, Peter C.; Dinmohamed, Avinash G.; Van Roon, Annika; Pijpers, Joyce; Van Roekel, Caren; Van den Hof, Susan; Hahné, Susan J.M.; De Gier, Brechje; Heijmans, Jarom; Nijhof, Inger S. |
| Source: |
Hofsink, Q, Lissenberg-Witte, B I, Haggenburg, S, Goorhuis, A, Hazenberg, M D, Rutten, C E, Den Tex, P, De Vries, E G E, Van der Veldt, A A M, Kemmeren, J M, De Keizer, N F, Huijgens, P C, Dinmohamed, A G, Van Roon, A, Pijpers, J, Van Roekel, C, Van den Hof, S, Hahné, S J M, De Gier, B, Heijmans, J & Nijhof, I S 2026, 'COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies : A Nationwide Cohort Study', Journal of Infectious Diseases, vol. 233, no. 2, pp. e363-e372. https://doi.org/10.1093/infdis/jiaf523 |
| Publication Year: |
2026 |
| Subject Terms: |
/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being |
| Description: |
Background In patients with hematologic malignancies, COVID-19 vaccine effectiveness is unknown and determinants of severe COVID-19 lack granularity. Methods To identify determinants of SARS-CoV-2 infection outcome we conducted a population-based, nationwide cohort study, including all adult Dutch residents who tested positive for SARS-CoV-2 between 1 June 2020, and 31 March 2022. Individuals were classified as having a (history of) hematologic malignancy, solid malignancy, or no malignancies. Primary outcome was severe COVID-19, defined as COVID-19-related hospitalization or death following first SARS-CoV-2 infection. Results Among 4 649 341 included individuals, those with hematologic malignancies were at highest risk of severe COVID-19. Vaccine effectiveness against severe COVID-19 in patients with hematologic malignancies was up to 74% (95% CI, 60% to 83%), depending on the SARS-CoV-2 variant period, the number of received vaccinations, and the time interval since vaccination. Risk of severe COVID-19 was highest for patients with recently diagnosed hematologic malignancies and declined over time, except for patients with chronic hematologic malignancies. Risk of severe COVID-19 tended to be higher in patients on tumor-specific treatment such as CD38 and CD20 antibodies, proteasome inhibitors, and protein kinase inhibitors. Conclusions COVID-19 vaccination lowered the risk of severe COVID-19 in SARS-CoV-2-infected patients with hematologic malignancies, although these patients remained at elevated risk compared with others. Determinants of severe COVID-19 included type of malignancy, time interval between malignancy diagnosis and SARS-CoV-2 infection, and treatment. These data can guide healthcare professionals in designing additional prevention and therapeutic strategies against respiratory virus infections for patients with hematologic malignancies. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
0022-1899; 1537-6613 |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41092195; info:eu-repo/semantics/altIdentifier/pissn/0022-1899; info:eu-repo/semantics/altIdentifier/eissn/1537-6613 |
| DOI: |
10.1093/infdis/jiaf523 |
| Availability: |
https://pure.eur.nl/en/publications/9e339a8d-1669-4e8e-b77c-8a3eebb5156c; https://doi.org/10.1093/infdis/jiaf523; https://pure.eur.nl/ws/files/228228812/jiaf523.pdf; https://www.scopus.com/pages/publications/105030522243 |
| Rights: |
info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.FD1E5813 |
| Database: |
BASE |